We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

107 hedge funds and large institutions have $120M invested in Corbus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

740% more call options, than puts

Call options by funds: $3.94M | Put options by funds: $469K

85% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 13

50% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 22

12% more capital invested

Capital invested by funds: $108M → $120M (+$12.6M)

7% more funds holding

Funds holding: 100 → 107 (+7)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3.12% less ownership

Funds ownership: 75.45% → 72.33% (-3.1%)

Holders
107
Holders Change
+7
Holders Change %
+7%
% of All Funds
1.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
24
Increased
33
Reduced
22
Closed
13
Calls
$3.94M
Puts
$469K
Net Calls
+$3.47M
Net Calls Change
+$2.96M

Top Buyers

Rank Fund Capital Flow
1
DP
Diadema Partners
New Jersey
+$3.7M
2
O
OrbiMed
New York
+$1.18M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$889K
4
PAP
Persistent Asset Partners
Hong Kong
+$881K
5
EAM
Exome Asset Management
New York
+$796K

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$7.77M
2
AC
Armistice Capital
New York
-$1.45M
3
Ameriprise
Ameriprise
Minnesota
-$1.1M
4
Citadel Advisors
Citadel Advisors
Florida
-$978K
5
HP
HealthInvest Partners
Sweden
-$873K
Name Holding Trade Value Shares
Change 		Change in
Stake
GI
76
GAMMA Investing
California
$3.15K -$421 -50 -13%
Nisa Investment Advisors
77
Nisa Investment Advisors
Missouri
$2.69K – – –
EWA
78
EverSource Wealth Advisors
Alabama
$1.95K -$42 -5 -2%
MCM
79
MAI Capital Management
Ohio
$1.18K – – –
GSEP
80
Golden State Equity Partners
California
$939 +$842 +100 New
Osaic Holdings
81
Osaic Holdings
Arizona
$807 – – –
GSWM
82
Golden State Wealth Management
California
$685 – – –
Carson Wealth (CWM LLC)
83
Carson Wealth (CWM LLC)
Nebraska
$648 -$674 -80 -54%
SWM
84
Spire Wealth Management
Virginia
$620 – – –
Jones Financial Companies
85
Jones Financial Companies
Missouri
$618 -$1.26K -150 -68%
AA
86
Ancora Advisors
Ohio
$601 – – –
FFO
87
Fortitude Family Office
Arizona
$601 +$539 +64 New
SS
88
SBI Securities
Japan
$488 – – –
National Bank of Canada
89
National Bank of Canada
Quebec, Canada
$428 +$387 +46 New
Wells Fargo
90
Wells Fargo
California
$410 – – –
SSG
91
Summit Securities Group
New York
$385 +$345 +41 New
HWM
92
HighMark Wealth Management
Minnesota
$384 – – –
NS
93
NBC Securities
Alabama
$309 – – –
CA
94
CoreCap Advisors
Michigan
$235 – – –
CW
95
Curio Wealth
Maryland
$216 – – –
NFSG
96
Newbridge Financial Services Group
Florida
$150 +$135 +16 New
VFM
97
Vision Financial Markets
Connecticut
$132 – – –
FGA
98
Fortis Group Advisors
New Jersey
$131 – – –
ASN
99
Advisory Services Network
Georgia
$131 +$118 +14 New
HI
100
Harbour Investments
Wisconsin
$122 +$109 +13 New
1 2 3
4
5

CRBP Hedge Fund Activity: Q1 2026 in Review

107 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2026, worth a combined $120M — up 12% from $108M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CRBP positions and 13 closed out — a net gain of 11 holders — while 33 added to existing stakes and 22 trimmed.

The largest buyer was Diadema Partners, opening a new position worth an estimated $3.7M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $7.77M sold.

  • 107 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2026, up from 100 in Q4 2025.
  • Funds reported $120M of Corbus Pharmaceuticals stock for Q1 2026, up 12% quarter-over-quarter.
  • 24 funds opened new Corbus Pharmaceuticals positions in Q1 2026 and 13 closed out, a net change of +11 holders.
  • The largest Corbus Pharmaceuticals buyer in Q1 2026 was Diadema Partners, an estimated $3.7M added.
  • The largest Corbus Pharmaceuticals seller in Q1 2026 was Octagon Capital Advisors, an estimated $7.77M sold.

Based on aggregated 13F filings for Q1 2026.